New drug combinations

Abstract

This patent application describes a new combination treatment of selective, noradrenaline-reuptake inhibitors (NARI) and specifically, reboxetine, and pindolol to provide rapid relief to patients suffering from depression, general anxiety, attention deficit hyperactivity disorder (ADHD), anxiety disorders such as obsessive compulsive disorders (OCD), panic disorders (PD), social phobia (SD) and the like.

1 . A single dosage form of reboxetine and pindolol.  
     
     
         2 . The single dose of  claim 1  where the form is a tablet, hard or soft capsule or caplet.  
     
     
         3 . The single dose of  claim 1  where the amount of reboxetine is 5 mg and the amount of pindolol is 7.5 mg.  
     
     
         4 . A method of treating a patient experiencing symptoms selected from; depression, general anxiety disorders (GADs), Addictive Disorders, attention deficit hyperactivity disorder (ADHD), and anxiety disorders such as obsessive compulsive disorder (OCD), panic disorder (PD), social phobia (SP), comprising the administration of a therapeutically effective, nontoxic dose of pindolol, its derivatives and or pharmaceutically acceptable salts thereof to a patient and administering a therapeutically effective, nontoxic dose of a selective, a noradrenaline reuptake inhibitor (NARI), its derivatives and or pharmaceutically acceptable salts thereof to a patient.  
     
     
         5 . A method of treating a patient as in  claim 4  where the noradrenaline reuptake inhibitor (NARI) is reboxetine.  
     
     
         6 . A method of treating a patient as in  claim 5  where the administration of the dose of pindolol is administered within 24 hours of the administration of the dose of reboxetine.  
     
     
         7 . The method of  claim 6  where the pindolol is administered within 12 hours of the reboxetine.  
     
     
         8 . The method of  claim 7  where the pindolol is administered within 6 hours of the reboxetine.  
     
     
         9 . The method of  claim 8  where the pindolol is administered within 3 hours of the reboxetine.  
     
     
         10 . The method of  claim 9  where the pindolol is administered within 1 hour of the reboxetine.  
     
     
         11 . The method of  claim 10  where the pindolol and reboxetine are administered concomitantly.  
     
     
         12 . The method of  claim 5  where the patient is experiencing symptoms of depression.  
     
     
         13 . The method of  claim 5  where the patient is experiencing symptoms of general anxiety disorders (GADs).  
     
     
         14 . The method of  claim 5  where the patient is experiencing symptoms of Addictive Disorders.  
     
     
         15 . The method of  claim 5  where the patient is experiencing symptoms of attention deficit hyperactivity disorder (ADHD).  
     
     
         16 . The method of  claim 5  where the patient is experiencing symptoms of obsessive compulsive disorder (OCD).  
     
     
         17 . The method of  claim 5  where the patient is experiencing symptoms of panic disorder (PD).  
     
     
         18 . The method of  claim 5  where the patient is experiencing symptoms of social phobia (SP).  
     
     
         19 . The use of reboxetine and pindolol, their derivatives and or pharmaceutically acceptable salts thereof in the manufacture of a medicament comprising an effective, nontoxic dose of reboxetine and pindolol to treat general anxiety disorders (GADs), Addictive Disorders, attention deficit hyperactivity disorder (ADHD), and anxiety disorders such as obsessive compulsive disorder (OCD), panic disorder (PD), social phobia (SP), and/or for the treatment of any of the symptoms of those diseases.  
     
     
         20 . The method or use in claims  1 - 19  where the reboxetine dose range is from about 4 to 10 mg. per patient per day and the pindolol dose range is from about 10 to 20 mg. per patient per day, delivered twice a day.  
     
     
         21 . The method or use in claims  1 - 19  where the reboxetine dose range is from about 6 to 8 mg. per patient per day and the pindolol dose range is from about 10 to 16 mg. per patient per day, delivered twice a day.